一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括SHR-A1811；Trastuzumab；Pertuzumab，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
SHR-A1811；Trastuzumab；Pertuzumab · II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Written informed consent before any study-specific procedure and willingness to comply with study visits and sample collection.
- 2. Female, aged 18 years or older.
- 3. Histologically confirmed invasive breast carcinoma at initial diagnosis, without distant metastasis.
- 4. HER2-positive tumor at initial diagnosis, defined as IHC 3+ or IHC 2+ with ISH amplification; hormone receptor status must be known.
- 5. Initial clinical anatomic stage IIB-IIIC according to the AJCC 8th edition.
- 6. Completion of at least 6 cycles and at least 16 weeks of standard neoadjuvant systemic therapy.
- 7. Definitive breast surgery and appropriate axillary staging or dissection, with pathologically complete resection.
- 8. Pathologic complete response, defined as no residual invasive carcinoma in the breast or regional lymph nodes (ypT0/is ypN0); residual ductal carcinoma in situ is permitted.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07856303；登记信息更新于 2026-10-02；本站同步于 2026-10-08，中国中心当前名额未经人工确认。